These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 9831287)

  • 1. Endocannabinoids.
    Mechoulam R; Fride E; Di Marzo V
    Eur J Pharmacol; 1998 Oct; 359(1):1-18. PubMed ID: 9831287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids and brain injury: therapeutic implications.
    Mechoulam R; Panikashvili D; Shohami E
    Trends Mol Med; 2002 Feb; 8(2):58-61. PubMed ID: 11815270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression.
    Mechoulam R
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):93-9. PubMed ID: 12052029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond THC and Endocannabinoids.
    Pacher P; Kogan NM; Mechoulam R
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():637-659. PubMed ID: 31580774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and isolation of anandamide and other endocannabinoids.
    Hanus LO
    Chem Biodivers; 2007 Aug; 4(8):1828-41. PubMed ID: 17712821
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
    Di Marzo V; Bisogno T; De Petrocellis L; Melck D; Martin BR
    Curr Med Chem; 1999 Aug; 6(8):721-44. PubMed ID: 10469888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabimimetic plants: are they new cannabinoidergic modulators?
    Kumar A; Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Memo M; Mastinu A
    Planta; 2019 Jun; 249(6):1681-1694. PubMed ID: 30877436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis.
    Mechoulam R; Ben-Shabat S
    Nat Prod Rep; 1999 Apr; 16(2):131-43. PubMed ID: 10331283
    [No Abstract]   [Full Text] [Related]  

  • 9. 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves.
    Kurihara J; Nishigaki M; Suzuki S; Okubo Y; Takata Y; Nakane S; Sugiura T; Waku K; Kato H
    Jpn J Pharmacol; 2001 Sep; 87(1):93-6. PubMed ID: 11676206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural and synthetic endocannabinoids and their structure-activity relationships.
    Palmer SL; Khanolkar AD; Makriyannis A
    Curr Pharm Des; 2000 Sep; 6(13):1381-97. PubMed ID: 10903399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quest for a vascular endothelial cannabinoid receptor.
    Kunos G; Bátkai S; Offertáler L; Mo F; Liu J; Karcher J; Harvey-White J
    Chem Phys Lipids; 2002 Dec; 121(1-2):45-56. PubMed ID: 12505689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
    Hillard CJ
    Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):3-18. PubMed ID: 10785538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges.
    Schmid HH; Schmid PC; Berdyshev EV
    Chem Phys Lipids; 2002 Dec; 121(1-2):111-34. PubMed ID: 12505695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance.
    Mallet PE; Beninger RJ
    Life Sci; 1998; 62(26):2431-9. PubMed ID: 9651110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716.
    Higgs S; Williams CM; Kirkham TC
    Psychopharmacology (Berl); 2003 Feb; 165(4):370-7. PubMed ID: 12447606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoids and vascular function.
    Hillard CJ
    J Pharmacol Exp Ther; 2000 Jul; 294(1):27-32. PubMed ID: 10871291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoids: new targets for drug development.
    Di Marzo ; Bisogno T; De Petrocellis L
    Curr Pharm Des; 2000 Sep; 6(13):1361-80. PubMed ID: 10903398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of endogenous cannabinoids.
    Martin BR; Mechoulam R; Razdan RK
    Life Sci; 1999; 65(6-7):573-95. PubMed ID: 10462059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of endocannabinoids--the plot thickens.
    Kunos G; Járai Z; Varga K; Liu J; Wang L; Wagner JA
    Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):71-84. PubMed ID: 10785543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
    Darmani NA
    J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.